Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Biofrontera Inc. (BFRI)
USD1.06
+0.00 (+0.00%)
US NASDAQ Healthcare Medical - Pharmaceuticals
Address
660 Main Street 1801
Woburn, MA, US
Woburn, MA, US
CEO
Hermann Lübbert
Website
biofrontera-us.com
IPO
2021-10-29
CIK 1858685 ISIN US09077D2099
Also trades on
Deutsche Börse · B8F.DE (EUR)
Deutsche Börse · B8FK.DE (EUR)
London Stock Exchange · 0DOL.L (EUR)
NASDAQ Capital Market · BFRIW (USD)
NASDAQ Capital Market · BFRA (USD)
NASDAQ Capital Market · BFRI (USD)
Other OTC · BFFTF (USD)
Other OTC · BFAGY (USD)
Description
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.06
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
214.6K
Beta
0.85
Float Shares
9.73M
Free Float %
81.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.00% | -14.03% | -9.30% | +26.96% | +20.90% | +73.44% | +41.43% | -87.80% | -98.88% | -98.88% | -98.88% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
1.06
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-6.45
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Pharmaceuticals: +7.8%+11.8% ★ Q1'26: +17.4% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+72.1% ★ Q1'26: +46.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-29.4% Q1'26: -0.7% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-21.9% Q1'26: -42.8% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%-89.3% Q1'26: -231.1% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+111.2% Q1'26: +111.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-0.74× Q1'26: -0.45× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
24.10M
est: 24.15M (-0.2%)
|
28.67M
est: 28.85M (-0.6%)
|
34.07M
est: 35.24M (-3.3%)
|
37.30M
est: 39.30M (-5.1%)
|
41.71M
est: 40.75M (+2.3%)
|
46.76M
46.65M – 46.86M
+14.7% YoY
|
54.70M
54.57M – 54.82M
+17.0% YoY
|
63.36M
63.22M – 63.51M
+15.8% YoY
|
80.08M
79.90M – 80.26M
+26.4% YoY
|
96.99M
96.77M – 97.20M
+21.1% YoY
|
| EBITDA |
-36.76M
est: -11.07M (-232.0%)
|
934.0K
est: -13.23M (+107.1%)
|
-18.45M
est: -15.14M (-21.9%)
|
-14.44M
est: -16.88M (+14.4%)
|
-8.28M
est: -17.50M (+52.7%)
|
-20.08M
-20.13M – -20.04M
-14.7% YoY
|
-23.49M
-23.54M – -23.44M
-17.0% YoY
|
-27.21M
-27.28M – -27.15M
-15.8% YoY
|
-34.39M
-34.47M – -34.32M
-26.4% YoY
|
-41.65M
-41.75M – -41.56M
-21.1% YoY
|
| EBIT |
-37.30M
est: -11.71M (-218.4%)
|
-238.0K
est: -13.99M (+98.3%)
|
-19.52M
est: -16.01M (-21.9%)
|
-15.63M
est: -17.85M (+12.4%)
|
-9.15M
est: -18.51M (+50.6%)
|
-21.24M
-21.29M – -21.19M
-14.7% YoY
|
-24.85M
-24.90M – -24.79M
-17.0% YoY
|
-28.78M
-28.85M – -28.72M
-15.8% YoY
|
-36.37M
-36.46M – -36.29M
-26.4% YoY
|
-44.05M
-44.15M – -43.95M
-21.1% YoY
|
| Net Income |
-37.71M
est: -308.36M (+87.8%)
|
-640.0K
est: -4.96M (+87.1%)
|
-20.13M
est: -51.68M (+61.0%)
|
-17.76M
est: -35.35M (+49.8%)
|
-10.54M
est: -16.19M (+34.9%)
|
-407.7K
-408.9K – -406.5K
+97.5% YoY
|
1.63M
1.63M – 1.64M
+500.0% YoY
|
2.91M
2.90M – 2.92M
+78.6% YoY
|
4.31M
4.30M – 4.32M
+48.0% YoY
|
5.24M
5.23M – 5.26M
+21.6% YoY
|
| SGA |
37.21M
est: 28.07M (+32.5%)
|
35.87M
est: 33.53M (+7.0%)
|
39.13M
est: 40.57M (-3.5%)
|
33.84M
est: 45.24M (-25.2%)
|
38.13M
est: 46.91M (-18.7%)
|
53.82M
53.70M – 53.94M
+14.7% YoY
|
62.96M
62.82M – 63.10M
+17.0% YoY
|
72.94M
72.77M – 73.10M
+15.8% YoY
|
92.18M
91.97M – 92.39M
+26.4% YoY
|
111.64M
111.39M – 111.89M
+21.1% YoY
|
| EPS |
-44.10
est: -55.90 (+21.1%)
|
-0.61
est: -0.90 (+32.2%)
|
-13.02
est: -4.44 (-193.5%)
|
-3.22
est: -3.04 (-6.1%)
|
-1.04
est: -1.39 (+25.2%)
|
-0.04
-0.04 – -0.03
+97.5% YoY
|
0.14
0.14 – 0.14
+500.0% YoY
|
0.25
0.25 – 0.25
+78.6% YoY
|
0.37
0.37 – 0.37
+48.0% YoY
|
0.45
0.45 – 0.45
+21.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-9.09M
OE per share TTM
-0.87
Owner's Yield
-78.71%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
4.4%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
7
Total invested
851.9K
Insider transactions (90d)
0
Beneficial owners (>5%)
30
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Wilhelm Konrad Thomas Zours | 9.18M | 38.97% | — | 9.18M | — | 9.18M | IN | — | 2022-09-19 | ↗ |
| 2 | Konrad Thomas Zours | 8.84M | 37.52% | — | 8.84M | — | 8.84M | IN | — | 2022-08-25 | ↗ |
| 3 | Consulting GmbH | 3.15M | 11.80% | 3.15M | — | 3.15M | — | CO | Germany | 2022-11-04 | ↗ |
| 4 | Alexander Link | 1.18M | 5.00% | — | 1.18M | — | 1.18M | IN | — | 2022-09-19 | ↗ |
| 5 | Delphi Unternehmensberatung Aktiengesellschaft | 1.18M | 5.00% | — | 1.18M | — | 1.18M | OO | — | 2022-09-19 | ↗ |
| 6 | Deutsche Balaton Aktiengesellschaft | 1.18M | 5.00% | — | 1.18M | — | 1.18M | OO | — | 2022-09-19 | ↗ |
| 7 | Rolf Birkert | 1.18M | 5.00% | — | 1.18M | — | 1.18M | IN | — | 2022-09-19 | ↗ |
| 8 | VV Beteiligungen Aktiengesellschaft | 1.18M | 5.00% | — | 1.18M | — | 1.18M | OO | — | 2022-09-19 | ↗ |
| 9 | Balaton Aktiengesellschaft | 835.7K | 3.55% | — | 835.7K | — | 835.7K | OO | — | 2022-08-25 | ↗ |
| 10 | Beteiligungen Aktiengesellschaft | 835.7K | 3.55% | — | 835.7K | — | 835.7K | OO | — | 2022-08-25 | ↗ |
| 11 | Birkert | 835.7K | 3.55% | — | 835.7K | — | 835.7K | IN | — | 2022-08-25 | ↗ |
| 12 | Link | 835.7K | 3.55% | — | 835.7K | — | 835.7K | IN | — | 2022-08-25 | ↗ |
| 13 | Unternehmensberatung Aktiengesellschaft | 835.7K | 3.55% | — | 835.7K | — | 835.7K | OO | — | 2022-08-25 | ↗ |
| 14 | Laurence W. Lytton | 508.9K | 11.00% | 508.9K | — | 508.9K | — | IN | USA | 2024-03-20 | ↗ |
| 15 | Gilad Aharon | 504.3K | 9.90% | — | 504.3K | — | 504.3K | IN | ONTARIO, CANADA | 2024-03-20 | ↗ |
| 16 | Rosalind Master Fund L.P. | 504.3K | 9.90% | — | 504.3K | — | 504.3K | PN | ONTARIO, CANADA | 2024-03-20 | ↗ |
| 17 | Steven Salamon | 504.3K | 9.90% | — | 504.3K | — | 504.3K | IN | ONTARIO, CANADA | 2024-03-20 | ↗ |
| 18 | The Hewlett Fund LP | 504.2K | 9.90% | — | — | — | — | PN | New York | 2024-05-07 | ↗ |
| 19 | Michael Bigger | 502.8K | 9.99% | — | — | — | 502.8K | IN | Delaware | 2024-03-15 | ↗ |
| 20 | 27-4413262 | 501.4K | 9.90% | 501.4K | — | 501.4K | — | OO | Maryland | 2024-03-20 | ↗ |
| 21 | Identification Nos. of above persons (. | 501.4K | 9.90% | 501.4K | — | 501.4K | — | IN | Maryland | 2024-03-20 | ↗ |
| 22 | Nabil Saad | 337.8K | 6.09% | 337.8K | — | 337.8K | — | IN | Canada | 2024-09-12 | ↗ |
| 23 | Bigger Capital Fund GP, LLC | 251.4K | 4.90% | — | — | — | 251.4K | OO | Delaware | 2024-03-15 | ↗ |
| 24 | Bigger Capital Fund, LP | 251.4K | 4.90% | — | — | — | 251.4K | PN | Delaware | 2024-03-15 | ↗ |
| 25 | District 2 Capital Fund LP | 251.4K | 4.90% | — | — | — | 251.4K | PN | Delaware | 2024-03-15 | ↗ |
| 26 | District 2 Capital LP | 251.4K | 4.90% | — | — | — | 251.4K | PN | Delaware | 2024-03-15 | ↗ |
| 27 | District 2 GP LLC | 251.4K | 4.90% | — | — | — | 251.4K | OO | Delaware | 2024-03-15 | ↗ |
| 28 | District 2 Holdings LLC | 251.4K | 4.90% | — | — | — | 251.4K | OO | Delaware | 2024-03-15 | ↗ |
| 29 | Armistice Capital, LLC | 168.1K | 9.99% | — | 168.1K | — | — | IA, OO | Delaware | 2024-02-14 | ↗ |
| 30 | Steven Boyd | 168.1K | 9.99% | — | 168.1K | — | — | HC, IN | Delaware | 2024-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
7
-7 vs prev Q
New positions
2
Closed positions
9
Increased
5
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ROSALIND ADVISORS, INC. | 1.14M +— (+0.0%) | 650.2K -473.4K (-42.1%) | 10.59% -1.613 pp | 0.23% -0.156 pp | USD1.25 -54.4% | 8 qtrs — |
| 2 | AIGH CAPITAL MANAGEMENT LLC | 915.2K -130.8K (-12.5%) | 521.7K -508.7K (-49.4%) | 8.49% -2.693 pp | 0.13% -0.164 pp | USD1.35 -57.8% | 8 qtrs — |
| 3 | VANGUARD GROUP INC | 114.0K +— (+0.0%) | 65.0K -47.3K (-42.1%) | 1.06% -0.161 pp | 0.00% +0.000 pp | USD0.98 -41.8% | 2 qtrs — |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 65.7K +23.1K (+54.2%) | 37.4K -4.5K (-10.8%) | 0.61% +0.154 pp | 0.00% +0.000 pp | USD0.76 -25.0% | 7 qtrs — |
| 5 | JANE STREET GROUP, LLC | 32.8K +32.8K (+100.0%) | 18.7K +18.7K (+100.0%) | 0.30% +0.305 pp | 0.00% +0.000 pp | USD0.57 +0.0% | 1 qtrs NEW |
| 6 | XTX TOPCO LTD | 18.9K +864.0 (+4.8%) | 10.8K -7.0K (-39.4%) | 0.18% -0.017 pp | 0.00% -0.001 pp | USD0.80 -28.8% | 3 qtrs — |
| 7 | TWO SIGMA SECURITIES, LLC | 13.5K -7.3K (-35.2%) | 7.7K -12.8K (-62.5%) | 0.13% -0.097 pp | 0.00% -0.002 pp | USD0.98 -41.8% | 5 qtrs — |
| 8 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 11.5K +11.5K (+100.0%) | 6.6K +6.6K (+100.0%) | 0.11% +0.107 pp | 0.00% +0.000 pp | USD0.57 +0.0% | 1 qtrs NEW |
| 9 | UBS GROUP AG | 10.4K +9.4K (+949.1%) | 5.9K +4.9K (+507.2%) | 0.10% +0.086 pp | 0.00% +0.000 pp | USD0.58 -1.7% | 7 qtrs — |
| 10 | SANCTUARY ADVISORS, LLC | 10.1K +10.1K (+100.0%) | 5.8K +5.8K (+100.0%) | 0.09% +0.094 pp | 0.00% +0.000 pp | USD0.57 +0.0% | 1 qtrs NEW |
| 11 | BLACKROCK, INC. | 4.6K +— (+0.0%) | 2.6K -1.9K (-42.1%) | 0.04% -0.007 pp | 0.00% +0.000 pp | USD1.33 -57.1% | 6 qtrs — |
| 12 | SBI SECURITIES CO., LTD. | 300.00 -1.0 (-0.3%) | 171.00 -125.0 (-42.2%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.08 -47.2% | 5 qtrs — |
| 13 | BANK OF AMERICA CORP /DE/ | 82.00 +12.0 (+17.1%) | 47.00 -22.0 (-31.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.80 -28.8% | 9 qtrs — |
| 14 | CITIGROUP INC | 1.00 -5.8K (-100.0%) | 1.00 -5.8K (-100.0%) | 0.00% -0.063 pp | 0.00% +0.000 pp | USD— | 2 qtrs — |
| 15 | RENAISSANCE TECHNOLOGIES LLC | — -18.7K (-100.0%) | — -18.4K (-100.0%) | 0.00% -0.200 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 16 | HUNTER ASSOCIATES INVESTMENT MANAGEMENT LLC | — -11.4K (-100.0%) | — -11.0K (-100.0%) | 0.00% -0.122 pp | 0.00% -0.002 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 61.8K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
6.00
Bullish
Ratio by volume
3.00
Bullish
Buys
12
Sells
2
Shares acquired
780.0K
Shares disposed
225.0K
Cash buys
—
Cash sales
—
Net activity
+555,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-05 | Luebbert Hermann | Director / Officer | M-Exempt | A | Common Stock | 137,500 | 0.00 | — | 290,211 | D | ↗ |
| 2026-03-05 | Leffler Eugene Frederick | Officer | M-Exempt | D | Restricted Stock Units | 87,500 | 0.00 | — | 0 | D | ↗ |
| 2026-03-04 | Weber Kevin Daniel | Director | A-Award | A | Employee stock option (right to buy) | 20,000 | 0.90 | 18.0K | 20,000 | D | ↗ |
| 2026-03-04 | Luebbert Hermann | Director / Officer | A-Award | A | Employee stock option (right to buy) | 125,000 | 0.90 | 112.5K | 125,000 | D | ↗ |
| 2026-03-04 | Leffler Eugene Frederick | Officer | A-Award | A | Employee stock option (right to buy) | 62,500 | 0.90 | 56.3K | 62,500 | D | ↗ |
| 2026-03-04 | Lanckriet Heikki | Director | A-Award | A | Employee stock option (right to buy) | 20,000 | 0.90 | 18.0K | 20,000 | D | ↗ |
| 2026-03-04 | Jones George Patrick | Officer | A-Award | A | Employee stock option (right to buy) | 50,000 | 0.90 | 45.0K | 50,000 | D | ↗ |
| 2026-03-04 | Hoffman Beth J. | Director | A-Award | A | Employee stock option (right to buy) | 20,000 | 0.90 | 18.0K | 20,000 | D | ↗ |
| 2026-03-04 | BORER JOHN J III | Director | A-Award | A | Employee stock option (right to buy) | 20,000 | 0.90 | 18.0K | 20,000 | D | ↗ |
| 2025-09-16 | de la Huerta Martinez Maria del Pilar | Director / 10% Owner | — | — | Series D Convertible Preferred Stock | 4,831,172 | 0.00 | 2.9K | 0 | I | ↗ |
| 2025-09-16 | Zours Wilhelm Konrad Thomas | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 400,000 | I | ↗ |
| 2025-09-16 | VV Beteiligungen Aktiengesellschaft | 10% Owner | — | — | Series D Convertible Preferred Stock | 4,831,172 | 0.62 | 3.02M | 0 | I | ↗ |
| 2025-09-16 | Plaggemars Hansjoerg | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-09-16 | Link Christian Alexander Ansgar | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-09-16 | DEUTSCHE BALATON AKTIENGESELLSCHAFT | 10% Owner | — | — | Series D Convertible Preferred Stock | 4,831,172 | 0.62 | 3.02M | 0 | I | ↗ |
| 2025-09-16 | DELPHI UNTERNEHMENSBERATUNG AKTIENGESELLSCHAFT | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 58,884 | I | ↗ |
| 2025-09-16 | Biofrontera AG | Director / 10% Owner | P-Purchase | A | Series D Convertible Preferred Stock | 3,019 | 0.00 | 1.81 | 3,019 | D | ↗ |
| 2025-09-15 | Jones George Patrick | Officer | A-Award | A | Employee stock option (right to buy) | 100,000 | 1.00 | 100.0K | 100,000 | D | ↗ |
| 2025-09-10 | Luebbert Hermann | Director / Officer | M-Exempt | A | Common Stock | 137,500 | 0.00 | — | 152,711 | D | ↗ |
| 2025-09-10 | Leffler Eugene Frederick | Officer | M-Exempt | A | Common Stock | 87,500 | 0.00 | — | 87,500 | D | ↗ |
| 2025-08-25 | Jones George Patrick | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-07-22 | Weber Kevin Daniel | Director | A-Award | A | Employee stock option (right to buy) | 20,000 | 1.00 | 20.0K | 20,000 | D | ↗ |
| 2025-07-22 | Luebbert Hermann | Director / Officer | A-Award | A | Employee stock option (right to buy) | 125,000 | 1.00 | 125.0K | 125,000 | D | ↗ |
| 2025-07-22 | Leffler Eugene Frederick | Officer | A-Award | A | Restricted Stock Units | 62,500 | 0.00 | — | 62,500 | D | ↗ |
| 2025-07-22 | Lanckriet Heikki | Director | A-Award | A | Employee stock option (right to buy) | 20,000 | 1.00 | 20.0K | 20,000 | D | ↗ |
| 2025-07-22 | Hoffman Beth J. | Director | A-Award | A | Employee stock option (right to buy) | 20,000 | 1.00 | 20.0K | 20,000 | D | ↗ |
| 2025-07-22 | BORER JOHN J III | Director | A-Award | A | Employee stock option (right to buy) | 20,000 | 1.00 | 20.0K | 20,000 | D | ↗ |
| 2025-06-30 | Biofrontera AG | Director | — | — | Common Stock | 0 | 0.00 | — | 400,000 | D | ↗ |
| 2024-07-12 | Weber Kevin Daniel | Director | A-Award | A | Employee stock option (right to buy) | 20,000 | 1.38 | 27.6K | 21,100 | — | ↗ |
| 2024-07-12 | Luebbert Hermann | Director / Officer | A-Award | A | Employee stock option (right to buy) | 275,000 | 1.38 | 379.5K | 290,211 | — | ↗ |
| 2024-07-12 | Leffler Eugene Frederick | Officer | A-Award | A | Employee stock option (right to buy) | 175,000 | 1.38 | 241.5K | 180,000 | — | ↗ |
| 2024-07-12 | Lanckriet Heikki | Director | A-Award | A | Employee stock option (right to buy) | 20,000 | 1.38 | 27.6K | 20,000 | — | ↗ |
| 2024-07-12 | Hoffman Beth J. | Director | A-Award | A | Employee stock option (right to buy) | 20,000 | 1.38 | 27.6K | 21,100 | — | ↗ |
| 2024-07-12 | BORER JOHN J III | Director | A-Award | A | Employee stock option (right to buy) | 20,000 | 1.38 | 27.6K | 21,100 | — | ↗ |
| 2024-05-18 | Luebbert Hermann | Director / Officer | M-Exempt | A | Common Stock | 4,771 | 0.00 | — | 15,211 | — | ↗ |
| 2023-07-03 | Lanckriet Heikki | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-05-18 | Monaco Erica L. | Officer | M-Exempt | D | Restricted Stock Units | 76,336 | 0.00 | — | 76,336 | — | ↗ |
| 2023-05-18 | Luebbert Hermann | Director / Officer | M-Exempt | A | Common Stock | 95,420 | 0.00 | — | 208,799 | — | ↗ |
| 2023-01-10 | Leffler Eugene Frederick | Officer | A-Award | A | Employee stock option (right to buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-11-14 | Gates Erica F. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-10-24 | Leffler Eugene Frederick | — | — | — | — | — | — | — | 0 | — | ↗ |
| 2022-05-18 | Wedge Loretta M. | Director | A-Award | A | Employee stock option (right to buy) | 22,000 | 0.00 | — | 22,000 | — | ↗ |
| 2022-05-18 | Weber Kevin Daniel | Director | A-Award | A | Employee stock option (right to buy) | 22,000 | 0.00 | — | 22,000 | — | ↗ |
| 2022-05-18 | Monaco Erica L. | Officer | A-Award | A | Restricted Stock Units | 152,672 | 0.00 | — | 209,361 | — | ↗ |
| 2022-05-18 | Luebbert Hermann | Officer | A-Award | A | Restricted Stock Units | 190,840 | 0.00 | — | 304,219 | — | ↗ |
| 2022-05-18 | Hoffman Beth J. | Director | A-Award | A | Employee stock option (right to buy) | 22,000 | 0.00 | — | 22,000 | — | ↗ |
| 2022-05-18 | Gates Erica F. | Director / Officer | A-Award | A | Employee stock option (right to buy) | 19,084 | 0.00 | — | 39,492 | — | ↗ |
| 2022-05-18 | BORER JOHN J III | Director | A-Award | A | Employee stock option (right to buy) | 22,000 | 0.00 | — | 22,000 | — | ↗ |
| 2022-03-02 | Weber Kevin Daniel | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-09 | Monaco Erica L. | Officer | A-Award | A | Employee stock option (right to buy) | 56,689 | 4.77 | 270.4K | 56,689 | — | ↗ |
| 2021-12-09 | Luebbert Hermann | Director / Officer | A-Award | A | Employee stock option (right to buy) | 113,379 | 4.77 | 540.8K | 113,379 | — | ↗ |
| 2021-12-09 | Gates Erica F. | Officer | A-Award | A | Employee stock option (right to buy) | 20,408 | 4.77 | 97.3K | 20,408 | — | ↗ |
| 2021-11-02 | Wedge Loretta M. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-02 | Hoffman Beth J. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-11-02 | BORER JOHN J III | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-28 | Monaco Erica L. | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-28 | Luebbert Hermann | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-28 | Gates Erica F. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-28 | Biofrontera AG | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 8,000,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-104.0K
Shares Outstanding
12.01M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Prof. Hermann Luebbert Ph.D., Chairman and Chief Executive Officer | 489.7K | 192.5K | 112.6K | 73.1K | — | 5.3K | 873.2K | 21.27% | ↗ |
| 2 | 2025 | Fred Leffler, Chief Financial Officer | 371.0K | 89.8K | 56.3K | 36.6K | — | 551.00 | 554.2K | 16.76% | ↗ |
| 3 | 2025 | George Jones, Chief Commercial Officer | 96.9K | — | — | 60.5K | — | 213.00 | 157.6K | 38.38% | ↗ |
| 4 | 2024 | Prof. Hermann Luebbert Ph.D., Chairman and Chief Executive Officer | 482.0K | 296.6K | 291.5K | 226.6K | — | 6.2K | 1.30M | 39.77% | ↗ |
| 5 | 2024 | Prof. Hermann Luebbert Ph.D., Chairman and Chief Executive Officer | 482.0K | 296.6K | 291.5K | 226.6K | — | 6.2K | 1.30M | 39.77% | ↗ |
| 6 | 2024 | Fred Leffler, Chief Financial Officer | 364.2K | 138.3K | 185.5K | 144.2K | — | 406.00 | 832.6K | 39.60% | ↗ |
| 7 | 2024 | Fred Leffler, Chief Financial Officer | 364.2K | 138.3K | 185.5K | 144.2K | — | 406.00 | 832.6K | 39.60% | ↗ |
| 8 | 2023 | Prof. Hermann Luebbert Ph.D., Chairman and Chief Executive Officer | 470.5K | 258.8K | — | — | — | 3.9K | 733.2K | 0.00% | ↗ |
| 9 | 2023 | Fred Leffler, Chief Financial Officer | 355.0K | 23.2K | — | 63.1K | — | 366.00 | 441.7K | 14.29% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hermann Luebbert | Chief Executive Officer, President & Chairman | 687.5K | — |
| Eugene Frederick Leffler | Chief Financial Officer | 461.3K | male |
| Daniel Hakansson | Senior Corporate Counsel | — | male |
| Jon Lyons | Vice President of Scientific & Medical Affairs | — | male |
| Samantha Widdicombe | Senior Vice President of Sales & Marketing | — | female |
| George Jones | Chief Commercial Officer | — | male |
| Erica F. Gates | Senior Director of Finance & Principal Accounting Officer | — | female |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BFRI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
